Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?

Roger Li; Philippe E. Spiess; Ashish M. Kamat

doi:10.1016/j.eururo.2018.04.012

Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?

Roger Li, Philippe E. Spiess, Ashish M. Kamat

Urology

Research output: Contribution to journal › Editorial › peer-review

10 Scopus citations

Abstract

Treatment options are limited for non–muscle-invasive bladder cancer patients having failed BCG treatment who cannot undergo cystectomy. While results from ongoing clinical trials are awaited, data have emerged suggesting that combination of agents having previously demonstrated safety and efficacy in this setting can help a large percentage of our patients. These data should not be ignored.

Original language	English (US)
Pages (from-to)	405-408
Number of pages	4
Journal	European urology
Volume	74
Issue number	4
DOIs	https://doi.org/10.1016/j.eururo.2018.04.012
State	Published - Oct 2018

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2018.04.012

Cite this

@article{86c93a9f4c244bf796bf0b2b2fb7b2ca,

title = "Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?",

abstract = "Treatment options are limited for non–muscle-invasive bladder cancer patients having failed BCG treatment who cannot undergo cystectomy. While results from ongoing clinical trials are awaited, data have emerged suggesting that combination of agents having previously demonstrated safety and efficacy in this setting can help a large percentage of our patients. These data should not be ignored.",

author = "Roger Li and Spiess, {Philippe E.} and Kamat, {Ashish M.}",

note = "Publisher Copyright: {\textcopyright} 2018 European Association of Urology",

year = "2018",

month = oct,

doi = "10.1016/j.eururo.2018.04.012",

language = "English (US)",

volume = "74",

pages = "405--408",

journal = "European urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Treatment Options for Patients with Recurrent Tumors After BCG Therapy

T2 - Are We Ignoring the Obvious?

AU - Li, Roger

AU - Spiess, Philippe E.

AU - Kamat, Ashish M.

PY - 2018/10

Y1 - 2018/10

N2 - Treatment options are limited for non–muscle-invasive bladder cancer patients having failed BCG treatment who cannot undergo cystectomy. While results from ongoing clinical trials are awaited, data have emerged suggesting that combination of agents having previously demonstrated safety and efficacy in this setting can help a large percentage of our patients. These data should not be ignored.

AB - Treatment options are limited for non–muscle-invasive bladder cancer patients having failed BCG treatment who cannot undergo cystectomy. While results from ongoing clinical trials are awaited, data have emerged suggesting that combination of agents having previously demonstrated safety and efficacy in this setting can help a large percentage of our patients. These data should not be ignored.

UR - http://www.scopus.com/inward/record.url?scp=85045960198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045960198&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2018.04.012

DO - 10.1016/j.eururo.2018.04.012

M3 - Editorial

C2 - 29685644

AN - SCOPUS:85045960198

SN - 0302-2838

VL - 74

SP - 405

EP - 408

JO - European urology

JF - European urology

IS - 4

ER -

Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this